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doi:10.1016/j.ejvs.2011.08.008Abstract Objectives: To analyse perioperative and midterm outcomes of carotid artery
stenting (CAS) for symptomatic >50% and asymptomatic >70% restenosis after open carotid
surgery (OCS).
Design: A multicentric retrospective study.
Methods: Outcome measures 30-day death, neurologic and anatomic (thrombosis, restenosis)
events. Univariant and multivariant logistic regression analyses were performed to identify
predictive factors for neurologic and anatomic events.
Results: A total of 249 patients with a mean age of 69 years (range, 45e88) were treated for
asymptomatic (86%) or symptomatic (14%) restenosis. The 30-day combined operative
mortality and stroke morbidity was 2.8% in asymptomatic patients and 2.9% in symptomatic
patients. Events during follow-up (mean duration, 29 months) included stroke in four cases,
TIA in two, stent thrombosis in four and restenosis in 21. KaplaneMeier estimates of overall
survival, neurologic-event-free survival, anatomic-event-free survival and reintervention-
free survival were 95.4%, 94.7%, 96.7% and 99.5%, respectively, at 1 year and 80.3%, 93.8%,
85.1% and 96%, respectively, at 4 years. Multivariant analysis showed that statin use was corre-
lated with a lower risk of anatomic events (odds ratio (OR)Z 0.15 (95% confidence interval (CI)
0.03e0.68), p Z 0.01) and that bypass was associated with a higher risk of anatomic events
than endarterectomy (OR Z 5.0 (95% CI 1.6e16.6), p Z 0.009).33 556 795 526.
hu-bordeaux.fr (D. Midy).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Endovascular Treatment of Carotid Restenosis 743Conclusion: CAS is a feasible therapeutic alternative to OCS for carotid restenosis with accept-
able risks in the perioperative period. Restenosis rate may be higher in patients treated after
bypass.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Reports describing long-term follow-up after carotid endar-
terectomy (CEA) indicate that restenosis with >50% diam-
eter reduction occurs in 6e37% of patients.1e3 However,
accompanying neurological events have been reported in
only 1e5% of these patients,4e6 raising doubt as to the
benefit of treating asymptomatic restenosis. Since the late
1990s, endovascular management of restenosis >50% has
been proposed as an alternative to re-operation based on
the rationale that redo open carotid surgery (OCS) under
local anaesthesia is challenging and technically more diffi-
cult than CEA due to scar tissue that increases the risk of
cranial nerve injury and hinders control of the internal
carotid artery in case of extensive lesions.7 According to
Recommendation 5 of the European Society For Vascular
Surgery (ESVS) guidelines regarding treatment for carotid
stenosis,8 carotid artery stenting (CAS) represents an alter-
native to redo CEA provided that the peri-interventional
stroke risk is <3%. To improve decision making, this multi-
centric retrospective study was carried out to analyse 30-day
and midterm outcomes of CAS for restenosis after OCS at 20
vascular surgery departments in France and Belgium.
Material and Methods
Study population
This retrospective study included patients who underwent
CAS for restenosis following CEA or carotid artery bypass
between January 1998 and July 2007 at 20 French and
Belgian vascular surgery departments with experience in
both OCS and CAS. Restenosis was defined as a diameter
reduction >50% measured by duplex scan and/or computed
tomography (CT) angiography. Indications for CAS in
patients with restenosis were symptomatic >50% and
asymptomatic >70% restenosis. Medical charts were
reviewed to extract demographic data, restenosis charac-
teristics and medications used. Details concerning the CAS
procedure, including type of cerebral protection device and
stent, were also noted. Patient selection for CAS was at the
discretion of each practitioner based on clinical experi-
ence, anatomic features affecting CAS feasibility, for
example, hostile aortic arch and contraindications for
general anaesthesia for redo CEA. None of the patients
included in this study was previously included in the EVA-3S
trial.9 This study was approved by the Institutional Review
Boards of each participating department. The number of
patients with restenosis who were not treated during the
study period was undeterminable.
Operative technique
Arterial access was achieved using the transfemoral
approach. After administering an intravenous bolus of heparin(50 UI/kg), the common carotid artery was cannulated using
an 8-F guiding catheter with 0.035-Terumo guidewire and
selective carotid angiography was performed to re-assess the
degree of restenosis and intracranial circulation. The 0.035-
guidewire was then replaced with a 0.014-guidewire to
facilitate passage through the stenosis. Predilatation was
performed in case of high-grade stenosis. In recent years,
placement of a cerebral protection device has become
routine. After deployment, the stent was expanded using
a balloon catheter. In some cases treated at the beginning of
the study, dilatation of restenosis was not followed by stent
placement. Completion angiography was performed to
determine the degree of residual stenosis. Atropin was used
selectively. Anti-platelet therapy with at least one drug was
administered before and after intervention.
Follow-up
None of the participating centres performed independent
neurologic assessment. Diagnosis of myocardial infarction
(MI) was based on the elevated troponin level measured
after chest pain, electrocardiogram (EKG) modification or,
in some centres, systematically. All patients underwent
post-procedural duplex scanning within 7 days and at 3e6
months, depending on the policy of each centre. The
interval between consecutive follow-up examinations with
duplex scans generally ranged from 6 to 12 months. In the
last years of the study, specific duplex criteria were used to
estimate intrastent restenosis: internal carotid artery/
common carotid artery ratio >2.7 and peak systolic velocity
220e339 cm s1 predict 50e79% stenosis, internal carotid
artery/common carotid artery ratio >4.15 and peak systolic
velocity >340 cm s1 predict 80% stenosis.
Definitions and end points
The degree of stenosis was assessed by CT angiography
according to criteria defined by the North American
Symptomatic Carotid Endarterectomy Trial (NASCET)
trial.10 Procedures were considered as technical successes
if stent deployment was achieved and if residual stenosis
was less than 20% after the procedure. Primary study
outcomes were 30-day postoperative death, neurologic
event (transient ischaemia attack (TIA) or stroke) and
anatomic events (restenosis or occlusion). Restenosis
following CAS was defined as greater than 50% narrowing
measured by duplex scan. Stroke was defined as neurologic
manifestations persisting more than 24 h and TIA was
defined as neurologic manifestations resolving within 24 h.
Neurologic events were classified as ipsilateral if they
affected the cerebral hemisphere on the same side as the
carotid stent and contralateral if they affected the cerebral
hemisphere on the opposite side from the carotid stent.
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All variables were expressed as means  standard deviation
(SD) or as numeric values (%). KaplaneMeier curves were
constructed to estimate overall survival, neurologic-event-
free survival, anatomic-event-free survival and reintervention-
free survival. Univariant analysis and multivariant logistic
regression analysis were performed to identify predictive
factors for neurologic and anatomic events. Risk factors
included in the analysis were age, gender, cardiovascular
history, vascular risk factors (diabetes, hypertension, hyper-
cholesterolaemia and smoking), interval between the first
carotid surgery and CAS (more or less than 2 years following
OCS), location of stenosis, degree of stenosis, symptomatic vs.
asymptomatic stenosis, contralateral carotid disease, stent
type (Wallstent (Boston Scientific, Natick, MA, USA) vs. other),
use of cerebral protection device, use of statins before and
after CAS and anti-platelet regimen. A probability value of
p < 0.05 was considered statistically significant.
Results
The charts of 249 patients who underwent CAS for restenosis
after OCS at 20 vascular surgery departments from January
1998 to July 2007 were retrospectively analysed. At time of
CAS, restenosis was asymptomatic in 214 patients (86%) and
symptomatic in 35 patients (14%). Patient data and reste-
nosis characteristics are shown in Table 1. Mean degree of
restenosis was 82.4  8% (60e95%) in symptomatic patients
and 82.4  7% (70e95%) in asymptomatic patients. Out the
214 asymptomatic restenosis, 36 (17%) were between 70%
and 80%. The mean interval between OCS and CAS for
restenosis was 43.4 months (range, 1e264). A total of 121
patients (48.6%) underwent CAS within 2 years after OCS.
Procedural details are presented in Table 2. Aortic arch
anatomywas documented in 173 cases; it was type I in 49.7%,
type II in 29.5% and type III in 20.8%. At the end of the study,
cerebral protection devices were used routinely as per
recommendations of the steering committee of the EVA-3S
trial.9 Preoperative and postoperative medications are lis-
ted in Table 3. Before 2003, patients were given aspirin alone
or with ticlopidin. From 2003 until the end of study, almost
all patients received aspirin and clopidogrel starting at least
48 h before the procedure and continuing for 1 month
thereafter. Treatment was then reduced to a single anti-
platelet agent. In the subgroup of 28 patients presenting
restenosis following bypass surgery, narrowing was symp-
tomatic in five cases (18%). The bypass was from the common
carotid artery to internal carotid artery. A prosthetic graft
was used in 12 cases (43%). Restenosis was located at the
proximal anastomosis in eight cases (29%), distal anasto-
mosis in 18 (64%) and mid-bypass in two (7%). The mean
interval between bypass and CAS for restenosis was 27.7
months (range, 1e84). The procedure was performed under
general anaesthesia in five cases (18%) and required the use
of an embolic protection device in 10 (36%).
Thirty-day outcome
The technical success rate was 99.6%. The one failure
occurred in apatientwhopresented abovine archpreventingcatheterisation of the common carotid artery and developed
stroke. No residual stenosis was observed. In one symptom-
atic and eight asymptomatic patients including the previous
patient, neurologic events, that is, seven strokes and 2 TIAs
that were all ipsilateral, were observed during the post-
operative period (Table 4). In two of these cases, completion
angiography depicted abnormal findings, that is, distal
dissection equiring emergency saphenous vein bypass graft-
ing in a patient who developed stroke and stent thrombus
despite aspiration in a patientwhodevelopedTIA. Nopatient
developed MI. The 30-day combined stroke and death rate
(CSDR) was 2.8% in asymptomatic patients and 2.9% in
symptomatic patients (Table 5). In the group of patients that
did not develop neurologic complication following techni-
cally successful CAS, there were two complications, that is,
vasospasm that was resolved by direct nitroprussiate injec-
tion and dissection of the common carotid artery that was
successfully treated by stent placement. Additional post-
operative morbidity included groin haematoma in two cases
and false aneurysm of the femoral artery in three, including
one requiring surgical revision.
Long-term outcome
Mean follow-up was 29 months (range, 1e156). Four
patients were lost to follow-up. Thirty patients died during
the study period. Causes of death included cardiovascular
disease in nine cases, cancer in seven, respiratory insuffi-
ciency in three, colonic ischaemia in one and unknown
causes in seven. In the remaining three cases, death was
due to neurologic events, that is, ipsilateral stroke in the
postoperative period, haemorrhagic stroke following
thrombolysis for limb ischaemia and ischaemic ipsilateral
stroke at 14 months with the last follow-up duplex scan
showing normal carotid flow. A total of six neurological
events occurred (Table 6). In three of these patients, the
event was related to stent thrombosis at 2, 5 and 24
months. In one patient, high-grade restenosis (80%) was
treated by repeat CAS at 61 months with no complications
at 11 months of follow-up. In the remaining two cases,
including the late fatal stroke, duplex scans were normal.
Follow-up duplex scan detected asymptomatic stent
occlusion at 6 months in one patient and asymptomatic
restenosis in 20 patients (Table 7). Six asymptomatic
restenosis 70% were treated by repeat angioplasty with no
complications. The rate of anatomic events during the 29-
months of follow-up period was 10% overall, 9.7% in the
asymptomatic group and 11.4% in the symptomatic group
(Table 8). KaplaneMeier estimates of overall survival,
neurologic-event-free survival, anatomic-event-free
survival and reintervention-free survival were 95.4%,
94.7%, 96.7% and 99.5%, respectively, at 1 year and 80.3%,
93.8%, 85.1% and 96%, respectively, at 4 years (Figs. 1e4).
Univariant and multivariant analysis
The location of the stenosis, that is, involving the common
or internal carotid artery, was not predictive for neurologic
or anatomic events. Univariant analysis identified no
predictive factors for postoperative neurologic events.
Conversely, multivariant analysis demonstrated an
Table 1 Characteristics, risk factors and previous carotid surgery and characteristics of restenosis in study population. TIA :
Transient Ischaemic Attack; CCA : Common Carotid Artery; ICA : Internal Carotid Artery.
Variable Asymptomatic Stenosis
N (%) or mean  SD (range)
Symptomatic Stenosis
N (%) or mean  SD (range)
Patients 214 35
Ipsilateral Stroke e 7 (20)
Ipsilateral TIA e 28 (80)
Age, y 69  8 (45e87) 71.2  8 (56e88)
Male 160 (75) 27 (77)
Female 54 (25) 8 (23)
Diabetes 48 (22) 7 (20)
Coronary artery disease 74 (35) 18 (51)
Hypertension 165 (77) 32 (91)
Smoking 145 (68) 22 (63)
Type of primary open carotid surgery
Endarterectomy 99 (46) 18 (51)
Endarterectomy and patch closure 68 (32) 9 (26)
Eversion 24 (11) 3 (9)
Bypass 23 (11) 5 (14)
Status of contralateral carotid artery
No significant lesions 127 (59) 20 (57)
Stenosis between 50 and 99% 49 (23) 8 (23)
Occlusion 38 (18) 7 (20)
Mean degree of restenosis 82.4  7 (70e95) 82.4  8 (60e95)
Restenosis location
Right side 99 (46) 23 (66)
Left side 115 (54) 12 (34)
CCA 31 (14) 5 (14)
Carotid bifurcation 45 (21) 7 (20)
ICA 149 (70) 26 (74)
Endovascular Treatment of Carotid Restenosis 745independent correlation between symptomatic restenosis
and risk of delayed neurologic events (odds ratio (OR)Z 14
(95% confidence interval (CI) 2.5.14e79.8), p Z 0.003).
Multivariant analysis also found that statins lowered theTable 2 Procedural details.
Variable Asymptomatic St
N (%) or mean 
Patients 214
General anaesthesia 31 (14)
Cerebral protection 100 (47)
Type of protection
Filter 85 (85)
Occlusive balloon 6 (6)
Unknown 9 (9)
Stenting 197 (92)
Type of stent
Wallstent 101 (51)
Acculink 48 (24.5)
Other 48 (24.5)
Stent design
Straight 168 (85)
Conic 29 (15)
Mean stent diameter, mm 7  1 (4e10)
Mean stent length, mm 31  8 (10e50)risk of anatomic events following CAS (OR Z 0.15 (95% CI
0.03e0.68), pZ 0.01) and that the risk of anatomic events
was higher after bypass than endarterectomy (OR Z 5.0
(95% CI 1.6e16.6), p Z 0.009).enosis
SD (range)
Symptomatic Stenosis
N (%) or mean  SD (range)
35
4 (11)
22 (63)
21 (95)
0
1 (5)
35 (100)
21 (60)
6 (17)
8 (23)
27 (77)
8 (23)
7  1 (5e10)
33  8 (20e50)
Table 3 Medication used before and after endovascular
treatment.
Treatment Preoperative Postoperative
Aspirin alone 18.9% 7.5%
Clopidogrela alone 15.7% 10%
Clopidogrela þ aspirin 54.6% 74.1%
Warfarin alone 3.8% 4.2%
Warfarin þ aspirin 7% 4.2%
Statin 27% 30.5%
a Before 2003, ticlopidine was used instead of clopidrogel.
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The indication for treatment of restenosis following OCS is
widely accepted for symptomatic patients with narrowing
>50%, but treatment for asymptomatic patients remains
controversial. In one recent review, Lal7 reported a low
complication rate after CAS and suggested 80% narrowing as
a threshold for considering treatment in asymptomatic
patients. In our study, the mean diameter of restenosis was
82%, and only 36 patients (17%) were asymptomatic
between 70% and 80%. By the end of this study, most of the
participating centres had adopted the 80% threshold value
for treatment of asymptomatic carotid restenosis.
Regarding 30-day outcomes in this study, the absence of
postoperative MI is intriguing. This occurred even though
coronary artery disease was present in one-third of the
patients and cardiovascular events accounted for 9 of the
23 deaths during follow-up. A possible explanation is that
only 14% of the CAS procedures required general anaes-
thesia. This view is in agreement with the results of the
recent Carotid Revascularization Endarterctomy versus
Stenting Trial (CREST) trial11 that showed a lower early MI
rate after CAS than OCS: 1.1% versus 2.3% (pZ 0.03). In the
CREST trial, 90% of OCS procedures were performed under
general anaesthesia.
With a 30-day CSDR of 2.8% in patients with asymptom-
atic restenosis and 2.9% in patients with symptomatic
restenosis, the 3% condition set for use of CAS by the ESVS
recommendation8 was met in our study. For comparison,Table 4 Characteristics of 9 patients presenting perioperative n
attack; m: month; DAP and SAP: dual or single antipatelet treatme
Patients Perioperative
Neurologic
Events
Sex/Age
(y)
Preoperative
Clinical Status
Interval
from OCS (m
1 Fatal Stroke M/85 TIA CEA, 18
2 TIA F/71 Asymptomatic CEA, 8
3 Stroke M/63 Asymptomatic CEA, 60
4 TIA F/55 Asymptomatic CEA, 70
5 Stroke M/68 Asymptomatic CEA, 14
6 Stroke F/62 Asymptomatic CEA, 84
7 Stroke M/74 Asymptomatic CEA, 27
8 Stroke M/77 Asymptomatic CEA, 170
9 Stroke M/70 Asymptomatic CEA, 2Table 8 lists 13 series (>30 patients) describing
endovascular treatment carotid restenosis following
OCS.12e24 In these series, the CSDR ranged from 0% to 5.9%.
In the largest series, that is, White et al.24 based on
a national registry, the CSDR was 3.8% in the 341 asymp-
tomatic patients but rose to 5.9% in the 188 symptomatic
patients.
By analysing the embolic load in cerebral protection
devices, Malik et al.25 showed that restenosis after CEA was
associated with minimal embolic generation in comparison
with primary stenosis and concluded that systematic use of
protection devices was not necessary during CAS for reste-
nosis. Regarding endovascular treatment of primary carotid
stenosis, the benefit of cerebral protection is still poorly
documented as specified in ESVS recommendations.8 The risk
of embolisation is presumably higher in association with
arterioscleroticdisease that is themost commoncauseof late
restenosis than with myointimal hyperplasia.7,26 In a study
focussing on the embolic load in cerebral protection devices
used during CAS for restenosis, Vos et al.22 found no signifi-
cant difference between patients treated for early versus
late restenosis. No correlation was found with the delay
between primary carotid revascularisation and CAS per-
formed for restenosis at more or less than 2 years after OCS.
A frequent statement echoed by physicians reluctant to
use CAS is that endovascular treatment is associated with
a higher incidence of late anatomic events, that is, reste-
nosis and thrombosis. As in our experience, recent
series27e29 describing OCS for restenosis after primary
surgical revascularisation have reported anatomic-event
rates ranging from 7.5% to 16%. In this regard, some stud-
ies30e32 have shown that the use of native-artery velocity
criteria in stented arteries leads to overestimation of the
degree of restenosis. Several authors32 have proposed
revised duplex velocity criteria for grading stenosis in
stented arteries and it is now generally accepted that an
internal/common carotid artery ratio >4.15 and peak
systolic velocity >340 cm s1 are predictive of 80% nar-
rowing. By the end of our study, most participating centres
were using these criteria.
Our multivariant analysis indicated that the risk of
anatomic events was higher after carotid bypass than
endarterectomy (OR Z 5.0 (95% CI 1.6e16.6), p Z 0.009).
This correlation between bypass and anatomic events iseurologic events. M: Male; F: Female; TIA: transient ischaemic
nt; MCA: middle cerebral artery; ICA: internal carotid artery.
)
Preoperative
Treatment
Embolic
Protection
Device
Completion
Angiogram
Postoperative
Treatment
DAP Filterwire Embols in MCA DAP
SAP Filterwire SAP
SAP SAP
SAP Filterwire DAP
SAP Filterwire ICA dissection SAP
SAP Filterwire DAP þ Statin
SAP SAP
DAP þ Statin Filterwire DAP þ Statin
SAP SAP
Table 5 Early postoperative complications (<30 days after the carotid artery stenting (CAS) for restenosis after open carotid
surgery (OCS)).
Early postoperative
complication (<30 days)
Overall population N (%) Asymptomatic N (%) Symptomatic N (%)
Patients 249 214 35
30-day combined stroke and
death rate
2.8 2.8 2.9
Death 1 (0.4) 0 (0) 1 (2.9)
Stroke 1 (0.4) 0 (0) 1 (2.9)
Nonfatal neurologic
complications
8 (3.2) 8 (3.7) 0 (0)
Stroke 6 (2.4) 6 (2.8) 0 (0)
Transient ischaemic attack 2 (0.8) 2 (0.9) 0 (0)
Myocardial infarction 0 (0) 0 (0) 0 (0)
Groin haematoma 2 (0.8) 2 (0.9) 0 (0)
Femoral artery false aneurysm 3 (1.2) 3 (1.4) 0 (0)
Endovascular Treatment of Carotid Restenosis 747consistent with the findings of Lauder et al.33 who reported
a 14% incidence of severe recurrent stenosis or occlusion
within 18 months after vein grafting and with the lower
complication rates reported by surgeons preferring
synthetic grafts.34 This suggests that enhanced duplex scan
surveillance is necessary in patients who undergo CAS for
restenosis following carotid bypass especially using vein
grafts.
Regarding postoperative medication, 75% of the occlu-
sions observed in our study occurred within 6 months after
CAS and dual-agent anti-platelet therapy had been
prescribed postoperatively in only one of these three cases.
At the end of our study, every patient underwent post-
operative dual-agent anti-platelet therapy for at least 1
month. The ESVS guidelines8 state that dual-agent anti-
platelet therapy is mandatory for at least 3 months.
Although the use of postoperative statins increased during
the course of our study, they were prescribed in only one-
third of patients. In a retrospective review of CAS for
high-grade symptomatic stenosis, Groschel et al.35
observed that postoperative statins reduce the overall
incidence of cardiovascular events. Furthermore, Verzini
et al.36 showed that statin use is associated with a lower
risk of perioperative and late ischaemic stroke and reduced
mortality rate. Although we did not observe this difference,Table 6 Characteristics of 6 patients presenting neurologic even
CEA: carotid endarterectomy; TIA: transient ischaemic attack; m
CAS: carotid artery stenting.
Patients Sex/Age, y First
OCS
Neurologic
Events
Delay
from
CAS, m
Preope
Cinica
1 M/65 CEA TIA 24 TIA
2 M/79 CEA Fatal Stroke 14 TIA
3 M/70 CEA TIA 72 TIA
4 M/64 Bypass Stroke 5 TIA
5 M/52 CEA TIA,62 62 Asymp
6 W/73 CEA Stroke 2 Asympour multivariant analysis showed that postoperative statin
medication lowered the risk of anatomic events (ORZ 0.15
(95% CI 0.03e0.68)).
The main limitations of this study are its retrospective
design with data collection from medical charts and the
lack of independent neurologic assessment. Our early
outcomes were good despite the fact that these procedures
coincided with the beginning of the CAS learning curve for
the participating surgeons. Caution is necessary in inter-
preting this high technical success rate as OCS was
preferred to CAS in patients with challenging anatomy
during the early period of this study. Due to the low inci-
dence of postoperative death and neurologic events, uni-
variant analysis was unable to identify risk factors for 30-
day morbidity/mortality. Regarding midterm outcomes,
multivariant analysis detected an independent correlation
between symptomatic restenosis and the risk of delayed
stroke or TIA (OR Z 14 (95% CI 2.46e79.8), p Z 0.003),
even though this complication occurred in only six patients
in our series (Table 6). These findings should be confirmed
by a randomised prospective control study with well-
defined anatomic criteria of symptomatic and possibly
high-grade asymptomatic carotid restenosis.
This study demonstrates that CAS is a feasible thera-
peutic alternative to OCS for carotid restenosis withts (>30-day). M: Male; F: Female; OCS: open carotid surgery;
: month; DAP and SAP: dual or single antipatelet treatment;
rative
l Status
Interval
from
OCS, m
Postoperative
Treatment
Duplex/CT
Exam
Tertiary
Procedure
84 DAP þ statin occlusion
82 DAP normal
9 SAP normal
25 SAP occlusion
tomatic 60 DAP 80 CAS
tomatic 17 SAP occlusion
Table 7 Late complications (>30 days after the carotid artery stenting (CAS) for restenosis following open carotid surgery
(OCS)). M: month.
Late complication
(>30 days)
Overall population
N (%) or mean
(range)
CEA
N (%) or mean
(range)
bypass
N (%) or mean
(range)
Asymptomatic
N (%) or mean
(range)
Symptomatic
N (%) or mean
(range)
Patients 249 221 28 214 35
Follow-up, m (range) 29 (1e156) 29 (1e156) 26 (1e73) 30 (1e156) 24 (1e84)
Ipsilateral neurologic
events
6 (2.4) 5 (2.3) 1 (3.6) 2 (0.9) 4 (9.4)
Stroke 4 (1.6) 3 (1.4) 1 (3.6) 1 (0.5) 2 (5.7)
Transient ischaemic
attack
2 (0.8) 2 (0.9) 0 1 (0.5) 2 (5.7)
Recurrent occlusive
disease
21 (8.4) 16 (7.2) 5 (17.9) 19 (8.9) 2 (5.7)
50e70% stenosis 16 (6.4) 14 (6.3) 2 (7.1) 14 (6.5) 2 (5.7)
71e99% stenosis 5 (2) 2 (0.9) 3 (10.7) 5 (2.3) 0 (0)
Ipsilateral carotid
occlusion
4 (1.6) 2 (0.9) 2 (7.1) 2 (0.9) 2 (5.7)
Tertiary intervention 7 (2.8) 4 (1.8) 3 (10.7) 7 (3.3) 0 (0)
Symptomatic lesions 1 (0.4) 1 0 1 (0.5) 0 (0)
Table 8 Early and long-term outcomes after carotid angioplasty and stenting for recurrent carotid stenosis (RCS) in series
describing 30 or more patients. Symp: symptomatic restenosis; Asymp: asymptomatic restenosis.
Author Period No Procedure Indication
to treat
30-day
CMSM %
Follow-up
(month)
Neurologic
Events %
Tertiary
RCS > 50% %
Carotid
Occlusion %
New (12) 1998eNS 218 symp
140 asymp
NS 3.7 14 0.6 6 0
Vitek (13) NS 44 symp
66 asymp
NS 4 20 0 NS NS
Bowser (14) 1997e2002 31 symp
21 asymp
>50%
>80%
4 26 2 16 0
Mc Donnell (15) 1994e2001 6 symp
24 asymp
>90% 3 20 0 10a 0
De Borst (16) 1998e2004 9 symp
47 asymp
>70%
>80%
0 36 3.5 19 1.7
Bettendorf (17) 2002e2006 10 symp
35 asymp
NS 3 10 0 6.1b 0
Kadhkhodayan (18) 1996e2005 29 symp
54 asymp
NS 3.6 22.4 6 4.8 0
Cuadra (19) 1996e2006 29 symp
89 asymp
>50%
>80%
5.1 NS NS NS NS
Mehta (20) 1996e2006 152 symp
71 asymp
>70%
>80%
1.4 NS NS NS NS
Attigah (21) 1989e2007 21 symp
24 asymp
>70%
>70%
0 24.8 0 NS NS
Vos (22) 1997e2006 14 symp
58 asymp
>70%
>80%
0 NS NS NS NS
Aburahma (23) 1996e2008 52 symp
68 asymp
>50%
>80%
0.8 24 0.8 14.2 0
White (24) 2005e2008 188 symp
341 asymp
NS 5.9
3.8
NS NS NS NS
Present Study 1998e2007 35 symp
214 asymp
>60%
>70%
2.9
2.8
30
24
2.4 8.4 1.6
a RCS > 90%.
b RCS > 80%.
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Figure 1 KaplaneMeier estimates of overall survival.
Figure 2 KaplaneMeier estimates of neurologic-event-free
survival.
Figure 4 KaplaneMeier estimates of reintervention-free
survival.
Endovascular Treatment of Carotid Restenosis 749acceptable risks in the 30-day postoperative period. The
restenosis rate may be higher in those presenting restenosis
after bypass, thus justifying enhanced duplex scan
surveillance.Figure 3 KaplaneMeier estimates of anatomic-event-free
survival.Conflict of Interest/Funding
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